Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have received a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $38.90.

DNLI has been the subject of a number of analyst reports. Jefferies Financial Group lifted their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Bank of America raised their target price on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. JPMorgan Chase & Co. dropped their price objective on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a research note on Thursday, November 7th. Finally, Raymond James reissued a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th.

Denali Therapeutics Stock Down 2.1 %

Shares of DNLI stock opened at $22.97 on Monday. The firm has a fifty day moving average of $26.28 and a 200-day moving average of $24.85. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.33. The company has a market capitalization of $3.31 billion, a price-to-earnings ratio of -8.32 and a beta of 1.35.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the prior year, the company earned ($0.72) EPS. On average, equities analysts expect that Denali Therapeutics will post -2.71 EPS for the current year.

Insiders Place Their Bets

In other news, Director Vicki L. Sato sold 1,020 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now owns 111,056 shares in the company, valued at approximately $3,331,680. The trade was a 0.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander O. Schuth sold 15,558 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total transaction of $465,339.78. Following the transaction, the insider now owns 178,066 shares in the company, valued at $5,325,954.06. The trade was a 8.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,578 shares of company stock valued at $2,474,440 in the last ninety days. 7.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors have recently added to or reduced their stakes in DNLI. CWM LLC grew its position in Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after buying an additional 654 shares during the period. Quest Partners LLC bought a new position in Denali Therapeutics during the third quarter valued at about $73,000. Assetmark Inc. grew its position in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after buying an additional 580 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after buying an additional 920 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Denali Therapeutics during the second quarter valued at about $194,000. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.